Table 4.

Associations of clinical factors with PV status among women with breast cancer

Clinical factor	Gene	Odds ratio	Lower 95% CI	Upper 95% CI	P-Value
Age of BC Dx (≤ 45 vs. > 45)	ATM	1.22	1.08	1.37	1.35E − 03
	CHEK2	1.34	1.21	1.47	4.34E − 09
	PALB2	1.12	0.98	1.27	9.40E − 02
	BRCA1	3.95	3.64	4.29	2.37E − 235
	BRCA2	1.98	1.84	2.14	4.54E − 70
	ATM, CHEK2, PALB2	1.24	1.16	1.33	1.14E − 10
	BRCA1/2	2.74	2.59	2.9	6.96E − 273
Female relative w/BC (Any vs. None)	ATM	1.47	1.30	1.66	1.02E − 09
	CHEK2	1.36	1.23	1.50	1.52E − 09
	PALB2	1.68	1.48	1.92	1.28E − 14
	BRCA1	1.91	1.76	2.07	1.87E − 54
	BRCA2	1.66	1.53	1.80	2.64E − 36
	ATM, CHEK2, PALB2	1.47	1.37	1.57	6.16E − 29
	BRCA1/2	1.78	1.68	1.88	4.39E − 85
Female relative w/BC (≤ 45 vs. > 45)	ATM	1.19	1.01	1.40	3.47E − 02
	CHEK2	1.21	1.06	1.39	4.83E − 03
	PALB2	1.24	1.05	1.46	1.33E − 02
	BRCA1	3.29	2.95	3.67	9.82E − 103
	BRCA2	1.90	1.71	2.10	1.73E − 34
	ATM, CHEK2, PALB2	1.21	1.11	1.33	2.20E − 05
	BRCA1/2	2.47	2.29	2.66	1.31E − 122

BC, breast cancer; CI, confidence interval; Dx, diagnosis

All models were adjusted for personal history of ovarian and pancreatic cancer, and family history of ovarian, pancreatic, prostate, male breast cancer, and ancestry